tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
PremiumThe FlyArcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
2M ago
Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
Premium
Ratings
Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
2M ago
Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
Premium
The Fly
Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
2M ago
Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs
PremiumThe FlyArcutis Biotherapeutics initiated with a Neutral at Goldman Sachs
3M ago
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
Premium
Company Announcements
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
3M ago
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
Premium
The Fly
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
4M ago
Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
PremiumRatingsBuy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
5M ago
Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
5M ago
Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100